Traders Purchase Large Volume of Call Options on Arvinas (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors purchased 5,428 call options on the stock. This is an increase of 155% compared to the typical daily volume of 2,130 call options.

Arvinas Price Performance

Shares of ARVN stock traded up $0.22 during mid-day trading on Friday, hitting $18.28. The stock had a trading volume of 1,922,945 shares, compared to its average volume of 1,074,012. Arvinas has a 12-month low of $15.53 and a 12-month high of $49.76. The firm has a market capitalization of $1.26 billion, a P/E ratio of -6.60 and a beta of 1.95. The firm's 50-day moving average is $18.22 and its two-hundred day moving average is $22.38.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the previous year, the business posted ($2.53) earnings per share. Analysts expect that Arvinas will post -3.81 EPS for the current year.

Insider Transactions at Arvinas

In other news, insider Ian Taylor sold 9,020 shares of the company's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the sale, the insider now directly owns 159,121 shares of the company's stock, valued at $2,658,911.91. This represents a 5.36 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John G. Houston sold 31,338 shares of the company's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. This trade represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 41,572 shares of company stock valued at $695,030 in the last ninety days. Corporate insiders own 5.23% of the company's stock.

Remove Ads

Institutional Investors Weigh In On Arvinas

Several hedge funds have recently made changes to their positions in ARVN. GF Fund Management CO. LTD. purchased a new stake in shares of Arvinas during the 4th quarter worth $28,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock worth $61,000 after purchasing an additional 440 shares during the last quarter. KBC Group NV lifted its stake in shares of Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after purchasing an additional 1,255 shares during the last quarter. Quantbot Technologies LP lifted its stake in shares of Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock worth $108,000 after purchasing an additional 2,601 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Arvinas during the 4th quarter worth $171,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ARVN has been the topic of several analyst reports. Wedbush reissued an "outperform" rating and set a $57.00 target price on shares of Arvinas in a research report on Tuesday, February 11th. Barclays cut their target price on Arvinas from $48.00 to $32.00 and set an "overweight" rating on the stock in a research report on Monday, February 3rd. Cantor Fitzgerald reissued an "overweight" rating on shares of Arvinas in a research report on Friday, February 7th. Oppenheimer boosted their target price on Arvinas from $40.00 to $45.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Finally, HC Wainwright reissued a "buy" rating and set a $87.00 target price on shares of Arvinas in a research report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $56.58.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.